The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism

European Journal of Pharmacology

Volumn 632, Issue 1-3, 2010, Pages 52-59

  Gessner, Guido ^a   Macianskiene, Regina ^b,c   Starkus, John G ^c   Schönherr, Roland ^a   Heinemann, Stefan H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

Amiodarone; Human ether go go related gene; K+ channel opener; KB130015; Patch clamp

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 2 METHYL 3 (3,5 DIIODO 4 CARBOXYMETHOXYBENZYL)BENZOFURAN; AMIODARONE; KB 130015; MALLOTOXIN; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHANNEL GATING; CONTROLLED STUDY; CYTOSOL; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ELECTRODE; HEART REPOLARIZATION; HUMAN; HUMAN CELL; KINETICS; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN BINDING; VOLTAGE CLAMP;

AMIODARONE; ANIMALS; BENZOFURANS; CELL LINE; ELECTRICITY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; KIDNEY; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; XENOPUS;

EID: 77349100802     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.010     Document Type: Article

References (34)

1. KS channel function induced by an LQT5 mutation and other IsK mutants. EMBO J. 18 (1999) 4137-4148
2. Carlsson B., Singh B.N., Temciuc M., Nilsson S., Li Y.-L., Mellin C., and Malm J. Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J. Med. Chem. 45 (2002) 623-630
3. Casis O., Olesen S.-P., and Sanguinetti M.C. Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol. Pharmacol. 69 (2006) 658-665
4. Chen J., Seebohm G., and Sanguinetti M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12461-12466
5. + conduction and selectivity. Science 280 (1998) 69-77
6. Fermini B., and Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev. Drug Discov. 2 (2003) 439-447
7. + channels. Circ. Res. 82 (1998) 386-395
8. + channels and relaxes vascular smooth muscle. Eur. J. Pharmacol. 555 (2007) 185-193
9. Hansen R.S., Diness T.G., Christ T., Demnitz J., Ravens U., Olesen S.-P., and Grunnet M. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1, 3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol. Pharmacol. 69 (2006) 266-277
10. Hosaka Y., Iwata M., Kamiya N., Yamada M., Kinoshita K., Fukunishi Y., Tsujimae K., Hibino H., Aizawa Y., Inanobe A., Nakamura H., and Kurachi Y. Mutational analysis of block and facilitation of HERG current by a class III antiarrhythmic agent nifekalant. Channels 1 (2007) 198-208
11. Jiang M., Dun W., Fan J.-S., and Tseng G.-N. Use-dependent 'agonist' effect of azimilide on the HERG channel. J. Pharmacol. Exp. Ther. 291 (1999) 1324-1336
12. + current. Circulation 103 (2001) 1317-1324
13. + channel. Mol. Pharmacol. 67 (2005) 827-836
14. Kiehn J., Thomas D., Karle C.A., Schöls W., and Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch. Pharmacol. 359 (1999) 212-219
15. Kodama I., Kamiya K., and Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 84 (1999) 20R-28R
16. + channel. Science 309 (2005) 897-903
17. Malykhina A.P., Shoeb F., and Akbarali H.I. Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus ocytes. Eur. J. Pharmacol. 452 (2002) 269-277
18. McManus O.B., Harris G.H., Giangiacomo K.M., Feigenbaum P., Reuben J.P., Addy M.E., Burka J.F., Kaczorowski G.J., and Garcia M.L. An activator of calcium-dependent potassium channels isolated from a medicinal herb. Biochemistry 32 (1993) 6128-6133
19. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12329-12333
20. Mubagwa K., Macianskiene R., Viappiani S., Gendviliene V., Carlsson B., and Brandts B. KB130015, a new amiodarone derivative with multiple effects on cardiac ion channels. Cardiovasc. Drug Rev. 21 (2003) 216-235
21. Ca channels by niflumic, flufenamic, and mefenamic acids. Biophys. J. 67 (1994) 2272-2279
22. Perry M., Sachse F.B., and Sanguinetti M.C. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 13827-13832
23. + channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Comm. 325 (2004) 883-891
24. Kr potassium channel. Cell 81 (1995) 299-307
25. Sanguinetti M.C., and Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 440 (2006) 463-469
26. Schönherr R., and Heinemann S.H. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J. Physiol. 493 (1996) 635-642
27. 2+/Calmodulin. EMBO J. 19 (2000) 3263-3271
28. Seebohm G. Activators of cation channels: potential in treatment of channelopathies. Mol. Pharmacol. 67 (2005) 585-588
29. Kr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr. Pharm. Des. 12 (2006) 2271-2283
30. Trudeau M.C., Warmke J.W., Ganetzky B., and Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269 (1995) 92-95
31. Xu X., Recanatini M., Roberti M., and Tseng G.-N. Probing the binding sites and mechanisms of action of two hERG channel activators, NS1643 and PD307243. Mol. Pharmacol. 73 (2008) 1709-1721
32. Zeng H., Lozinskaya I.M., Lin Z., Willette R.N., Brooks D.P., and Xu X. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J. Pharmacol. Exp. Ther. 319 (2006) 957-962
33. Zhou J., Augelli-Szafran C.E., Bradley J.A., Chen X., Koci B.J., Volberg W.A., Sun Z., and Cordes J.S. Novel potent human ether-à-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 68 (2005) 876-884
34. Zhou M., Morais-Cabral J.H., Mann S., and MacKinnon R. Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors. Nature 411 (2001) 657-661